Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Down 97.3% in January

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a significant decline in short interest in January. As of January 15th, there was short interest totaling 264 shares, a decline of 97.3% from the December 31st total of 9,733 shares. Based on an average daily volume of 27,414 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s stock are sold short. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 27,414 shares, the days-to-cover ratio is currently 0.0 days.

Matinas Biopharma Stock Performance

Shares of Matinas Biopharma stock traded down $0.01 during trading on Wednesday, hitting $0.71. The company’s stock had a trading volume of 7,801 shares, compared to its average volume of 35,521. Matinas Biopharma has a 52 week low of $0.47 and a 52 week high of $3.09. The company has a fifty day simple moving average of $0.71 and a two-hundred day simple moving average of $1.24. The company has a market capitalization of $4.54 million, a PE ratio of -0.21 and a beta of 1.28.

Matinas Biopharma (NYSEAMERICAN:MTNB) last issued its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.